Goldman Sachs (NYSE:GS) analyst Goldman Sachs maintained a Buy rating on Health Catalyst (NASDAQ:HCAT) on Friday, setting a price target of $60, which is approximately 12.72% above the present share price of $53.23.
expects Health Catalyst to post earnings per share (EPS) of -$1.01 for the second quarter of 2021.
The current consensus among 8 TipRanks analysts is for a Strong Buy rating of shares in Health Catalyst, with an average price target of $59.25.
The analysts price targets range from a high of $63 to a low of $52.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $53.28 million and a net profit of -$38.92 million. The company's market cap is $2.37 billion.
According to TipRanks.com, Goldman Sachs analyst Goldman Sachs is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 9.9% and a 59.59% success rate.
Health Catalyst, Inc. engages in the provision of data and analytics technology and services to healthcare organizations. It operates through the Technology, and Professional Services segments. The Technology segment includes its data platform, analytics applications, and support services. The Professional Services segment combines analytics, implementation, strategic advisory, outsource, and improvement services to deliver expertise to its customers. The company was founded by Steven C. Barlow and Thomas D. Burton in 2008 and is headquartered in Salt Lake City, UT.